BIFIDO Co., Ltd. was founded in 1999, in the spirit of challenge to pursue the best biotechnology and be the best in the field of the human microbiome. Among various intestinal microbiome, Bifidobacterium is considered to be the most beneficial bacterium to maintain healthy intestinal microbial balance. BIFIDO has focused on research and development of Bifidobacterium spp. since 1999. Over 250 related scientific papers and 80 patents prove that BIFIDO is the top-tier company with the greatest experience and expertise in the microbiome industry. Recently, BIFIDO started microbiome research on rheumatoid arthritis (RA), a chronic inflammatory disease. We analyzed the microbiota of RA patients and tried to find a way to treat even those who were less responsive to treatment. We have selected novel Bifidobacterium strains that can improve the symptoms of RA in animal models, and we expect new pharmabiotics from those strains. We are now expanding our pipelines for other immune-related diseases, including cancer.
